Zacks Investment Research·4 days ago
Aurinia (AUPH) Upgraded to Strong Buy: Here's WhyAurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aurinia Pharmaceuticals Inc.(AUPH)Earnings, Financials & Key Ratios
AUPH•NASDAQ
$15.80
7.6× P/E·Price updated Jul 2, 2026
AboutAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Show more
- Revenue$283M+20.4%
- EBITDA$114M+673.7%
- Net Income$287M+4893.1%
- EPS (Diluted)2.07+5167.2%
- Gross Margin88.46%+0.5%
- EBITDA Margin40.34%+542.7%
- Operating Margin37.06%+1959.5%
- Net Margin101.47%+4047.7%
- ROE59.91%+3834.1%
AUPH Price & Volume
Aurinia Pharmaceuticals Inc. (AUPH) stock price & volume — 10-year historical chart
Loading chart...
Operational Efficiency Gains Drive Improving Profitability Profiles
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:Single-product revenue concentration
Key Thesis Takeaways
- Aurinia has successfully transitioned from a cash-burning clinical-stage entity to a profitable commercial enterprise, evidenced by a 53.3% operating margin in 2026Q1.
- While the company has rationalized its R&D spend to $7.5M to bolster the bottom line, the long-term outlook remains tethered to the single-product performance of Lupkynis.
- Investors should monitor the sustainability of these margins as the company faces potential competitive pressures and relies on aggressive capital returns, such as the $36.2M in share repurchases executed in 2026Q1.
Verdict Logic
while the company demonstrates improved profitability with a 44.2% net margin in 2026Q1, the reliance on a single-product revenue stream and lumpy cash flow conversion warrants a cautious approach.
AUPH Growth Metrics
Aurinia Pharmaceuticals Inc. (AUPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years103.27%
5 Years41.38%
3 Years28.3%
TTM20.62%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM648.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM675.58%
Return on Capital
10 Years-26.72%
5 Years-13.06%
3 Years-0.87%
Last Year18.89%
AUPH Recent Earnings
Aurinia Pharmaceuticals Inc. (AUPH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (73%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.25+38.9%
$0.18
Rev
$78M+0.9%
$77M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.26+23.8%
$0.21
Rev
$77M+3.2%
$75M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.23+43.8%
$0.16
Rev
$73M-1.6%
$75M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.16-5.9%
$0.17
Rev
$70M+3.4%
$68M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.25vs $0.18+38.9% | $78Mvs $77M+0.9% |
| Q1 2026 | Feb 26, 2026 | $0.26vs $0.21+23.8% | $77Mvs $75M+3.2% |
| Q4 2025 | Nov 4, 2025 | $0.23vs $0.16+43.8% | $73Mvs $75M-1.6% |
| Q3 2025 | Jul 31, 2025 | $0.16vs $0.17-5.9% | $70Mvs $68M+3.4% |
Based on last 12 quarters of dataView full earnings history →
Latest AUPH News
Recent stock market news and headlines for Aurinia Pharmaceuticals Inc. (AUPH)
Zacks Investment Research·Jun 26, 2026
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerIndivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Zacks Investment Research·Jun 25, 2026
5 Small Drug Stocks to Invest in Amid a Biotech ComebackInnovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Zacks Investment Research·Jun 23, 2026
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Peers Comparison
Key metrics vs top competitors for Aurinia Pharmaceuticals Inc. (AUPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.80 | $2.03B | 7.63 | 20.38% | 101.47% | 59.91% | — | |
| $312.01 | $6.25B | 50.90 | 60.4% | 55.95% | 16.19% | — | |
| $83.05 | $1.89B | 25.02 | 43.78% | 9.71% | 17.32% | — | |
| $319.60 | $9.23B | -23.71 | -100% | — | -43.02% | — | |
| $88.48 | $9.5B | 107.90 | 12.79% | 6.23% | 7.5% | — | |
| $51.30 | $103.17B | 6.96 | 4.11% | 19.19% | 31.48% | — |
Compare AUPH vs Peers
Aurinia Pharmaceuticals Inc. (AUPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AUPH SEC Filings & Documents
Aurinia Pharmaceuticals Inc. (AUPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 3, 2026·SEC
10-K Annual Reports
410-Q Quarterly Reports
6Get notified when AUPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AUPH Frequently Asked Questions
Aurinia Pharmaceuticals Inc. (AUPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Aurinia Pharmaceuticals Inc.'s revenue?
Aurinia Pharmaceuticals Inc. (AUPH) reported $298.3M in revenue for fiscal year 2025. This represents a 38082% increase from $0.8M in 1998.
How fast is Aurinia Pharmaceuticals Inc. growing?
Aurinia Pharmaceuticals Inc. (AUPH) grew revenue by 20.4% over the past year. This is strong growth.
Is AUPH profitable?
Yes, Aurinia Pharmaceuticals Inc. (AUPH) is profitable, generating $298.2M in net income for fiscal year 2025 (101.5% net margin).
Dividend & Returns
What is AUPH's return on equity?
Aurinia Pharmaceuticals Inc. (AUPH) has a return on equity (ROE) of 59.9%. This is excellent, indicating efficient use of shareholder capital.
What is Aurinia Pharmaceuticals Inc.'s free cash flow?
Aurinia Pharmaceuticals Inc. (AUPH) generated $165.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.